Global Perspectives, an organization specialized in healthcare studies, is conducting a study to understand the relationship between narcolepsy symptoms and their effect on well-being. We are currently looking for patients diagnosed with narcolepsy, aged 18 years and above, to participate.  The study will be online and will consist of two successive surveys of about 30 min each within a time difference of 3 to 6 months between each survey. As a token of appreciation we are offering a 100USD incentive paid upon completion of the first survey and 65USD incentive upon completion of the seco ..read more

BOSTON and LONDON, April 22, 2024 (GLOBE NEWSWIRE) — Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug application (IND) to initiate a Phase 1 first-in-human, clinical trial of ORX750 for the treatment of narcolepsy. ORX750 is an investigational, orally administered, highly potent and selective orexin receptor 2 (OX2R) agonist designed to directly target the underlying pat ..read more

The purpose of this study is to evaluate the safety, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of MK-6552 in participants with Narcolepsy Type 1 (NT1). Part 1 will evaluate safety, tolerability, and PK of MK-6552 after administration of ascending doses in a single day to support a dose level decision for Part 2. Part 2 will investigate the PD of MK-6552 after single-day and multiple-day administration. Participants who complete Part 1 and demonstrate that they are able to tolerate at least one dose level of MK-6552 will participate in Part 2. View brochure here. Contact:  ..read more

This CNF survey helps understand caregivers’ experiences on their journey in child neurology. Caregivers of children with neurologic conditions can complete the brief survey through May 3rd here. This CNF survey helps understand clinicians’ and providers’ experiences in child neurology. Any healthcare professional working with children and youth with neurologic conditions can complete the brief survey through May 3rd here. Results will be shared with advocates and health care providers, so they are better able to serve families. The post Child Neurology Foundation (CNF) Needs Assessment Survey ..read more

PLYMOUTH MEETING, Pa., April 11, 2024 /PRNewswire/ — Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced an exclusive licensing agreement with Bioprojet to develop, manufacture and commercialize TPM-1116, a highly potent and selective oral orexin-2 receptor (OX2R) agonist that will be evaluated for the treatment of narcolepsy and other sleep/wake disorders. TPM-1116 represents a new chemical series of OX2R agonists with the potential for a best-in-class clinical profile. Check out the full article here or the PDF version here. The post Harmony Biosciences Announces ..read more

DUBLIN, April 9, 2024 /PRNewswire/ — Alkermes plc (Nasdaq: ALKS) today announced positive topline results from the narcolepsy type 2 (NT2) and idiopathic hypersomnia (IH) cohorts of a phase 1b, proof-of-concept study evaluating ALKS 2680, the company’s novel, investigational, oral orexin 2 receptor (OX2R) agonist in development as a once-daily treatment for narcolepsy. ALKS 2680 data demonstrated clinically meaningful and statistically significant improvements from baseline in mean sleep latency on the Maintenance of Wakefulness Test (MWT) compared to placebo at all doses tested ..read more

Join us on April 24th at 2pm ET for “Canada: Narcolepsy Medications & Access to Care!” This month, WUN is highlighting Narcolepsy medications and access to care in Canada with a special session presented by Laurel Charlesworth, MD & Kelsey Bingham, person with Narcolepsy. Bring your questions for this opportunity to “ask the experts!” Register now! Dr Laurel Charlesworth is a sleep physician and general neurologist at The Ottawa Hospital, and an Assistant Professor of Medicine at the University of Ottawa. She completed her medical degree at McMaster University’s Niagara Regional Campus ..read more

Dear Deb and the Wake Up Narcolepsy community, Today we announced positive top-line results from the Phase 2 clinical trial of KP1077 demonstrating clinically meaningful benefits for key idiopathic hypersomnia (IH) symptoms and providing critical information for the design of a Phase 3 study. You can read more about KP1077 and the top-line results announcement here. We want to extend our gratitude to those who participated in this trial and our patient advocacy group partners and supporters for making this clinical trial possible. Your partnership in raising awareness for this study and suppor ..read more

NEW YORK, March 25, 2024 (GLOBE NEWSWIRE) — Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that AXS-12 (reboxetine), a highly selective and potent norepinephrine reuptake inhibitor and cortical dopamine modulator, achieved the primary endpoint and significantly reduced the frequency of cataplexy attacks as compared to placebo in patients with narcolepsy in the SYMPHONY Phase 3 trial. AXS-12 also reduced excessive daytime sleepiness ..read more

Since inception in 2008, countless women have contributed to the mission and success of Wake Up Narcolepsy (WUN)! Today, in honor of Women’s History Month, we celebrate the women currently serving in WUN leadership roles. The woman who co-founded the organization and continues to serve as our Executive Director, never compromising on the vision she had in 2008: Monica Gow. The women on our Medical Advisory Board, helping us provide accurate content to the community and answer the community’s questions, all while seeing patients of their own and working to improve the lives of people living wit ..read more